AstraZeneca PLC
AZNHealthcare|Drug Manufacturers - General|UK
$202.83
-0.66 (-0.32%)
DCF (FCF)
$71.68
Earnings Power
$36.18
Financials
Financial Snapshot
Market Cap
$313.20B
Enterprise Value
$-23.19B
Revenue (TTM)
$58.74B
Net Income (TTM)
$10.22B
Cash & Equivalents
$5.72B
Net Cash/Share
$-38.07
Free Cash Flow (TTM)
$8.67B
Operating CF (TTM)
$14.57B
Debt/Equity
0.6
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $5.81B | $4.55B | $5.59B | $6.22B | $7.99B | $6.40B | $6.24B | $5.86B | $5.53B | $5.72B | $5.72B | |
| Operating Cash Flow | $4.14B | $3.58B | $2.62B | $2.97B | $4.80B | $5.96B | $9.81B | $10.35B | $11.86B | $14.57B | $14.57B | |
| Free Cash Flow | $1.83B | $1.96B | $1.25B | $509.0M | $2.19B | $3.76B | $7.24B | $6.57B | $7.28B | $8.67B | $8.67B | |
| Capital Expenditure | $-2.31B | $-1.62B | $-1.37B | $-2.46B | $-2.61B | $-2.20B | $-2.57B | $-3.78B | $-4.59B | $-5.91B | $-5.91B | |
| Financing Cash Flow | $-1.32B | $-2.94B | $-2.04B | $-1.76B | $-2.20B | $3.65B | $-6.82B | $-6.57B | $-4.00B | $-7.54B | $-7.54B |
R&D Spending
R&D (TTM)
$14.23B
R&D Intensity
24.2%
R&D Growth YoY
+0.0%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $23.00B | $22.46B | $22.09B | $24.38B | $26.62B | $37.42B | $44.35B | $45.81B | $54.07B | $58.74B | $58.74B | |
| R&D Expense | $5.89B | $5.76B | $5.93B | $6.06B | $5.99B | $9.74B | $9.76B | $10.94B | $13.58B | $14.23B | $14.23B | |
| R&D % of Revenue | 25.6% | 25.6% | 26.9% | 24.8% | 22.5% | 26.0% | 22.0% | 23.9% | 25.1% | 24.2% | 24.2% | |
| SG&A | $8.48B | $9.88B | $10.98B | $11.98B | $11.90B | $15.59B | $17.98B | $18.22B | $20.22B | $20.77B | $20.51B |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $23.00B | $22.46B | $22.09B | $24.38B | $26.62B | $37.42B | $44.35B | $45.81B | $54.07B | $58.74B | $58.74B | |
| Cost of Goods Sold | $4.13B | $4.32B | $4.94B | $4.92B | $5.30B | $12.44B | $12.39B | $8.27B | $10.21B | $10.63B | $10.63B | |
| Gross Profit | $18.88B | $18.15B | $17.15B | $19.46B | $21.32B | $24.98B | $31.96B | $37.54B | $43.87B | $48.11B | $48.11B | |
| R&D | $5.89B | $5.76B | $5.93B | $6.06B | $5.99B | $9.74B | $9.76B | $10.94B | $13.58B | $14.23B | $14.23B | |
| SG&A | $8.48B | $9.88B | $10.98B | $11.98B | $11.90B | $15.59B | $17.98B | $18.22B | $20.22B | $20.77B | $20.51B | |
| Operating Income | $4.83B | $2.71B | $516.0M | $1.74B | $3.92B | $-139.0M | $4.51B | $8.72B | $10.25B | $13.33B | $13.74B | |
| Interest Expense | $-1.37B | $-1.36B | $-1.37B | $-1.40B | $-1.27B | $-1.28B | $-1.33B | $-1.59B | $-1.68B | $-1.61B | $-1.71B | |
| Pretax Income | $3.55B | $2.23B | $1.99B | $1.55B | $3.92B | $-265.0M | $2.50B | $6.90B | $8.69B | $12.40B | $12.40B | |
| Net Income | $3.50B | $3.00B | $2.15B | $1.33B | $3.20B | $112.0M | $3.29B | $5.96B | $7.04B | $10.22B | $10.22B | |
| EPS (Diluted) | 2.76 | 2.37 | 1.70 | 1.03 | 2.44 | 0.08 | 2.11 | 3.81 | 4.50 | 6.54 | 6.55 | |
| EBITDA | $7.28B | $6.62B | $7.11B | $6.71B | $8.08B | $5.11B | $9.09B | $13.42B | $15.44B | $19.51B | $19.60B | |
| Shares Out. (M) | 1266.00 | 1267.00 | 1267.00 | 1301.00 | 1313.00 | 1427.00 | 1560.00 | 1562.00 | 1563.00 | 1562.00 | 1563.00 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.93B | $3.32B | $4.75B | $5.37B | $7.83B | $6.33B | $6.17B | $5.84B | $5.49B | $5.71B | $5.71B | |
| Marketable Securities | $884.0M | $1.23B | $849.0M | $849.0M | $160.0M | $69.0M | $77.0M | $20.0M | $37.0M | $8.0M | $8.0M | |
| Total Current Assets | $13.26B | $13.15B | $15.59B | $15.56B | $19.54B | $26.24B | $22.59B | $25.05B | $25.83B | $28.72B | $28.72B | |
| Total Assets | $62.53B | $63.35B | $60.65B | $61.38B | $66.73B | $105.36B | $96.48B | $101.12B | $104.03B | $114.07B | $114.07B | |
| Total Current Liabilities | $15.26B | $16.38B | $16.29B | $18.12B | $20.31B | $22.59B | $26.29B | $30.54B | $27.87B | $30.62B | $30.62B | |
| Long-Term Debt | $14.49B | $15.56B | $17.36B | $15.73B | $17.50B | $28.13B | $22.96B | $22.36B | $26.51B | $24.71B | $24.71B | |
| Total Liabilities | $45.86B | $46.71B | $46.61B | $46.78B | $51.09B | $66.08B | $59.42B | $61.95B | $63.16B | $65.36B | $65.36B | |
| Stockholders' Equity | $14.85B | $14.96B | $12.47B | $13.13B | $15.62B | $39.27B | $37.04B | $39.14B | $40.79B | $48.67B | $48.67B | |
| Retained Earnings | $8.14B | $8.22B | $5.68B | $2.81B | $5.30B | $1.71B | $-574.0M | $1.50B | $3.16B | $10.97B | $10.97B |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $4.14B | $3.58B | $2.62B | $2.97B | $4.80B | $5.96B | $9.81B | $10.35B | $11.86B | $14.57B | $14.57B | |
| Capital Expenditure | $-2.31B | $-1.62B | $-1.37B | $-2.46B | $-2.61B | $-2.20B | $-2.57B | $-3.78B | $-4.59B | $-5.91B | $-5.91B | |
| Free Cash Flow | $1.83B | $1.96B | $1.25B | $509.0M | $2.19B | $3.76B | $7.24B | $6.57B | $7.28B | $8.67B | $8.67B | |
| Investing Cash Flow | $-3.97B | $-2.33B | $963.0M | $-657.0M | $-285.0M | $-11.06B | $-2.96B | $-4.06B | $-7.98B | $-6.81B | $-6.81B | |
| Financing Cash Flow | $-1.32B | $-2.94B | $-2.04B | $-1.76B | $-2.20B | $3.65B | $-6.82B | $-6.57B | $-4.00B | $-7.54B | $-7.54B | |
| Issuance of Stock | $47.0M | $43.0M | $34.0M | $3.52B | $30.0M | $29.0M | $29.0M | $33.0M | $-43.0M | $-481.0M | $-481.0M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Issuance of Debt | $2.49B | $2.32B | $2.97B | $500.0M | $3.26B | $12.93B | $74.0M | $3.98B | $6.49B | $379.0M | $1.75B | |
| Payments of Debt | $-303.0M | $-1.75B | $-1.50B | $-2.02B | $-1.61B | $-5.04B | $-1.27B | $-4.94B | $-4.68B | $-2.03B | $-3.40B | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Change in Cash | $-1.13B | $-1.75B | $1.50B | $552.0M | $2.32B | $-1.51B | $-55.0M | $-346.0M | $-208.0M | $269.0M | $269.0M |
Dilution Tracker
Shares Outstanding
1563M
5-Year Share Growth
+9.5%
Stock Issuance (TTM)
$-481.0M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 1266.00 | 1267.00 | 1267.00 | 1301.00 | 1313.00 | 1427.00 | 1560.00 | 1562.00 | 1563.00 | 1562.00 | 1563.00 | |
| YoY Change % | — | 0.1% | 0.0% | 2.7% | 0.9% | 8.7% | 9.3% | 0.1% | 0.1% | -0.1% | 0.1% | |
| Stock Issuance | $47.0M | $43.0M | $34.0M | $3.52B | $30.0M | $29.0M | $29.0M | $33.0M | $-43.0M | $-481.0M | $-481.0M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 82.1% | 80.8% | 77.7% | 79.8% | 80.1% | 66.8% | 72.1% | 82.0% | 81.1% | 81.9% | 81.9% | |
| Operating Margin % | 21.0% | 12.1% | 2.3% | 7.1% | 14.7% | -0.4% | 10.2% | 19.0% | 19.0% | 22.7% | 23.4% | |
| Net Margin % | 15.2% | 13.4% | 9.8% | 5.5% | 12.0% | 0.3% | 7.4% | 13.0% | 13.0% | 17.4% | 17.4% | |
| EBITDA Margin % | 31.6% | 29.5% | 32.2% | 27.5% | 30.4% | 13.7% | 20.5% | 29.3% | 28.6% | 33.2% | 33.4% | |
| FCF Margin % | 8.0% | 8.7% | 5.6% | 2.1% | 8.2% | 10.1% | 16.3% | 14.3% | 13.5% | 14.8% | 14.8% | |
| ROE % | 21.0% | 20.1% | 15.7% | 10.4% | 22.2% | 0.4% | 8.6% | 15.6% | 17.6% | 22.9% | 23.1% | |
| ROA % | 5.7% | 4.8% | 3.5% | 2.2% | 5.0% | 0.1% | 3.3% | 6.0% | 6.9% | 9.4% | 9.3% | |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)31.16
Historical18.21 / 36.70 / 534.95
Industry Med.21.25
P/S5.43
Historical2.91 / 4.60 / 5.91
Industry Med.2.33
P/B6.53
Historical4.35 / 6.07 / 13.55
Industry Med.2.06
EV/EBITDA17.37
Historical10.80 / 17.47 / 53.39
Industry Med.13.04
EV/Revenue5.80
Historical3.51 / 5.21 / 6.60
Industry Med.2.48
P/FCF36.70
Historical22.01 / 40.62 / 263.48
Industry Med.23.48
Intrinsic Value Models
DCF (FCF Based)
$71.68
Peter Lynch Value
$148.69
Median P/S Value
$172.81
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | 20.07 | 28.96 | 43.73 | 96.78 | 40.35 | 1446.33 | 64.77 | 35.22 | 29.41 | 28.23 | 31.16 | |
| PS Ratio | 3.05 | 3.87 | 4.26 | 5.32 | 4.86 | 4.40 | 4.81 | 4.58 | 3.83 | 4.91 | 5.43 | |
| PB Ratio | 4.59 | 5.46 | 7.46 | 10.10 | 8.49 | 4.57 | 5.70 | 5.32 | 4.94 | 5.59 | 6.53 | |
| EV/EBITDA | 11.39 | 15.38 | 15.37 | 21.50 | 17.52 | 39.72 | 25.83 | 17.18 | 14.89 | 15.88 | 17.37 | |
| EV/Revenue | 3.60 | 4.53 | 4.95 | 5.92 | 5.32 | 5.43 | 5.29 | 5.03 | 4.25 | 5.27 | 5.80 |
Analyst Estimates & Quality
Altman Z-Score
3.96
Safe
Piotroski F-Score
8
Strong
Beneish M-Score
-2.54
Unlikely Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $64,621M | $68,746M | $72,824M |
| Net Income | $16,000M | $18,100M | $20,251M |
| EPS | 8.44 | 9.79 | 10.86 |
| Book Value per Share | 35.69 | 41.05 | 47.83 |
| Operating Cash Flow per Share | 11.20 | 10.95 | 13.66 |
| Operating CF | $17,511.51M | $17,117.82M | $21,345.62M |
Dividends
Dividend/Share (TTM)
$3.13
Dividend Yield
1.56%
Yield 10Y Median
2.60%
Frequency
Semi-annually
Recent Payments
| Ex-Date | Pay Date | Amount | Type |
|---|---|---|---|
| 2026-02-20 | 2026-03-23 | $1.595 | Cash Div. |
| 2025-08-07 | 2025-09-08 | $0.767 | Cash Div. |
| 2025-02-20 | 2025-03-24 | $1.68 | Cash Div. |
| 2024-08-08 | 2024-09-09 | $0.776 | Cash Div. |
| 2024-02-22 | 2024-03-25 | $1.56 | Cash Div. |
| 2023-08-10 | 2023-09-11 | $0.718 | Cash Div. |
| 2023-02-23 | 2023-03-27 | $1.628 | Cash Div. |
| 2022-08-11 | 2022-09-12 | $0.764 | Cash Div. |
| 2022-02-24 | 2022-03-28 | $1.453 | Cash Div. |
| 2021-08-12 | 2021-09-13 | $0.648 | Cash Div. |
| 2021-02-25 | 2021-03-29 | $1.374 | Cash Div. |
| 2020-08-13 | 2020-09-14 | $0.696 | Cash Div. |
| 2020-02-27 | 2020-03-30 | $1.464 | Cash Div. |
| 2019-08-08 | 2019-09-09 | $0.719 | Cash Div. |
| 2019-02-28 | 2019-03-27 | $1.468 | Cash Div. |
| 2018-08-09 | 2018-09-10 | $0.684 | Cash Div. |
| 2018-02-15 | 2018-03-19 | $1.336 | Cash Div. |
| 2017-08-10 | 2017-09-11 | $0.689 | Cash Div. |
| 2017-02-16 | 2017-03-20 | $1.9 | Cash Div. |
| 2016-08-11 | 2016-09-12 | $0.9 | Cash Div. |
Revenue Segments
By Business
| Segment | 2025 |
|---|---|
| Pharmaceuticals | $58.74B |
By Geography
| Segment | 2025 |
|---|---|
| US | $23.97B |
| Asia, Africa and Australasia | $2.72B |
| Australia | $454.0M |
| Canada | $954.0M |
| China | $6.64B |
| France | $1.41B |
| Germany | $2.89B |
| Italy | $1.08B |
| Japan | $3.56B |
| Rest of Europe | $4.32B |
| Spain | $1.14B |
| Sweden | $2.62B |
| The Americas | $2.63B |
| UK | $4.36B |